WHAT'S NEW

WuXi Acquires NextCODE Health to Create Global Leader in Genomic Medicine

WuXi Acquires NextCODE Health to Create Global Leader in Genomic Medicine

We are very pleased to share with you exciting news that marks another step towards the realization of WuXi’s vision. Read more.

WuXi NextCODE Genomics Invests in the Series B of Claritas Genomics

WuXi NextCODE Genomics Invests in the Series B of Claritas Genomics

Congratulation to our partner, Claritas Genomics, for securing $15 million in capital for its Series B round to expand its commercial operations, launch new next generation sequencing-based tests for diagnosis of pediatric genetic disorders... Read more.

WuXi’s STA Wins CMO Leadership Award

WuXi’s STA Wins CMO Leadership Award

We are pleased to share with you that SynTheAll Pharmaceutical Co., Ltd. (STA), our small-molecule manufacturing subsidiary, has won a 2015 CMO Leadership Award, which is presented by Life Science Leader ...Read more.

INNOVATION THAT MATTERS

Gene Therapy Offers Potentially New Treatment for beta-Thalassemia Patients

Gene Therapy Offers Potentially New Treatment for beta-Thalassemia Patients

Bluebird Bio Inc., a leading gene therapy biotech company based in Cambridge, Massachusetts, announced on February 2 that the U.S. Food and Drug Administration (FDA) has granted…Read more.

A New Weapon to Fight Breast Cancer

A New Weapon to Fight Breast Cancer

Congratulations to Pfizer for receiving accelerated approval for its investigational new drug, IBRANCE to treat advanced breast cancer from the U.S. FDA on February 3.  Read more.

FDA Approved Natpara, the First Biologic to Treat a Rare Disease, Hypoparathyroidism

FDA Approved Natpara, the First Biologic to Treat a Rare Disease, Hypoparathyroidism

NPS Pharmaceutical, Inc., headquartered in Bedminster, New Jersey, USA, won FDA approval on January 23, 2015 for Natpara, the first bioengineered replacement therapy ...Read more.

FDA Granted Breakthrough Status to Intercept’s Drug Obeticholic Acid (OCA) for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis

FDA Granted Breakthrough Status to Intercept’s Drug Obeticholic Acid (OCA) for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis

On January 29, Intercept Pharmaceuticals, Inc. (Intercept), headquartered in New York City, NY announced… Read more.

BCX4161, a Promising New Orally Administered Drug for the Rare and Genetic Disorder Hereditary Angioedema, Received Fast Track Status from the FDA

BCX4161, a Promising New Orally Administered Drug for the Rare and Genetic Disorder Hereditary Angioedema, Received Fast Track Status from the FDA

BioCryst Pharmaceuticals, Inc., a small pharmaceutical company headquartered in Durham, North Carolina…  Read more.

PERSPECTIVES

An Interview with Dr. Rick Panicucci, Vice President of Pharmaceutical Development Services

An Interview with Dr. Rick Panicucci, Vice President of Pharmaceutical Development Services

We are delighted to announce that Dr. Rick Panicucci has joined WuXi as Vice President of Pharmaceutical Development Services.  Read more.

EVENTS

3rd Annual WuXi Global Forum at JP Morgan Healthcare Conference a Great Success

3rd Annual WuXi Global Forum at JP Morgan Healthcare Conference a Great Success

On January 13 in San Francisco, WuXi hosted our 3rd Annual WuXi Global Forum – A Celebration of Global Partnerships. Over 500 influential industry leaders...  Read more.

WuXi Throws a Grand Annual Party

WuXi Throws a Grand Annual Party

WuXi colleagues recently celebrated Chinese New Year together on January 23  in Shanghai.  The event was attended by nearly 7000 WuXi employees from Shanghai, Beijing, Wuhan, Yangtze River region, and the U.S.. Read more.

Thank you for your support in helping WuXi reach where we are today. We will continue with our goal - to serve you better with our integrated technology and capability platform.
 Office of Corporate Communications, WuXi AppTec

Web: www.wuxiapptec.com | Email: communications@wuxiapptec.com